Abstract

### Diagnostic strategies The widespread application of specialist clinics for early evaluation of patients with chest pain has focused attention on the effectiveness of diagnostic testing. In a study of nearly 400 000 patients with suspected coronary artery disease, the diagnostic yield of cardiac catheterisation was only 37.6%, leading to calls for better strategies for risk stratification.1 As pointed out in correspondence, the low yield was probably due to verification bias, itself a consequence of basing referral decisions in low- risk populations on non-invasive tests such as exercise ECG.2 Similar considerations prompted the NICE guideline group to recommend a more selective approach to non-invasive testing based on a careful clinical assessment of disease probability in patients presenting with stable chest pain.3 For those, with unequivocal histories at the extremes of diagnostic probability ( 90%) no diagnostic tests were considered necessary, while for patients with a high probability of disease (60–90%) invasive angiography without prior ischaemia testing was recommended. The NICE call for CT calcium scoring in patients with a low (10–30%) probability of disease generated greatest concern, particularly after a report that 19% of patients without coronary calcification—who would have been ruled out for angina in the NICE algorithm—had obstructive (>50% stenosis) disease.4 However, the population referred for angiography in this study had a high pre-test probability of disease and in lower-risk populations CT calcium scoring retains a high diagnostic sensitivity.5 NICE recommendations were driven largely by cost-effectiveness analysis but whether they will improve the diagnostic yield of cardiac catheterisation remains to be seen. ### Circulating biomarkers in stable angina The clinical role of circulating biomarkers for diagnosis of obstructive coronary artery disease in patients with suspected angina has yet to be defined. In one study, blood samples for the N-terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP) and various inflammatory markers were …

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.